Shield Therapeutics PLC (GB:STX)
LSE:STX
Want to see GB:STX full AI Analyst Report?
Top Page
Shield Therapeutics
(LSE:STX)
Select Model
Select Model
Rating:41Neutral
Price Target:
6.00 p
▼(-39.09% Downside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by weak financial quality despite improving operating trajectory: the company is still loss-making with ongoing cash burn and negative equity. Technicals also weigh on the score, with the stock in a clear downtrend and bearish momentum, despite being oversold. Valuation is only mildly supportive because the negative P/E reflects current losses and there is no dividend yield provided.
Positive Factors
Strong revenue growth
Sustained +58.2% revenue growth to 50.7M in 2025 indicates expanding product uptake and market penetration for Accrufer. This revenue base supports scale economics, funds commercial investment, and underpins a multi-month path to improved profitability and strategic optionality.
Negative Factors
Persistent negative equity
A negative equity position signals structural balance-sheet weakness that limits shock absorption and heightens refinancing and dilution risk. Even with improving operations, negative net assets constrain strategic flexibility and make the company more dependent on external capital for durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained +58.2% revenue growth to 50.7M in 2025 indicates expanding product uptake and market penetration for Accrufer. This revenue base supports scale economics, funds commercial investment, and underpins a multi-month path to improved profitability and strategic optionality.
Read all positive factors
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£68.45M
Dividend YieldN/A
Average Volume (3M)3.16M
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue Growth49.81%
EPS Growth52.94%
CountryUK
Employees63
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,069,524,200
10 Day Avg. Volume1,665,963
30 Day Avg. Volume3,163,002
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£76.00M
Shield Therapeutics Business Overview & Revenue Model
Company Description
Shield Therapeutics plc is a specialized pharmaceutical firm dedicated to developing and commercializing innovative drugs at various clinical stages to address significant unmet medical requirements. Their flagship product, Accrufer/Feraccru, is a...
How the Company Makes Money
Shield Therapeutics makes money primarily by commercializing Accrufer (ferric maltol). Revenue is generated through product sales in markets where the company sells directly and through collaboration/licensing arrangements in markets where commerc...
Shield Therapeutics Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
27
Negative
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.74M | 31.51M | 16.54M | 5.50M | 1.52M |
| Gross Profit | 22.38M | 13.22M | 5.09M | 2.46M | -1.67M |
| EBITDA | -9.16M | -20.74M | -38.28M | -46.07M | -17.69M |
| Net Income | -18.03M | -26.61M | -33.29M | -40.44M | -19.34M |
Balance Sheet | |||||
| Total Assets | 65.24M | 57.42M | 48.39M | 22.07M | 44.41M |
| Cash, Cash Equivalents and Short-Term Investments | 11.63M | 7.02M | 17.63M | 2.82M | 12.12M |
| Total Debt | 30.15M | 26.34M | 25.80M | 6.10M | 156.00K |
| Total Liabilities | 80.32M | 58.74M | 26.49M | 16.65M | 3.38M |
| Stockholders Equity | -15.08M | -1.32M | 11.79M | 5.43M | 41.03M |
Cash Flow | |||||
| Free Cash Flow | -8.83M | -8.80M | -50.65M | -20.14M | -18.80M |
| Operating Cash Flow | -8.81M | -8.77M | -46.93M | -18.25M | -16.74M |
| Investing Cash Flow | -306.29K | -2.37M | -3.07M | -1.70M | -2.05M |
| Financing Cash Flow | 13.75M | 5.26M | 62.77M | 7.71M | 27.58M |
Shield Therapeutics Technical Analysis
Neutral
9.85
Price Trends
7.34
Negative
8.33
Negative
8.55
Negative
Market Momentum
-0.21
Negative
46.95
Neutral
68.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Neutral. The current price of 9.85 is above the 20-day moving average (MA) of 6.12, above the 50-day MA of 7.34, and above the 200-day MA of 8.55, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 46.95 is Neutral, neither overbought nor oversold. The STOCH value of 68.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:STX.
Shield Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £80.83M | 13.98 | 7.82% | ― | ― | ― | |
59 Neutral | £3.07B | 10.47 | 15.83% | 4.16% | 3.84% | 8.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £473.67M | -7.98 | 409.00% | ― | 2.94% | -32.00% | |
41 Neutral | £68.45M | -4.93 | 103.62% | ― | 49.81% | 52.94% |
* Healthcare Sector Average
GB:STX
Shield Therapeutics
6.40
3.98
163.92%
GB:AGY
Allergy Therapeutics
7.48
0.58
8.41%
GB:HIK
Hikma Pharmaceuticals
1,451.00
-518.20
-26.32%
GB:VLG
Venture Life
66.50
16.00
31.68%
Shield Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Shield Therapeutics awards CEO new share options to support growth of iron drug franchise
Positive
May 5, 2026
Shield Therapeutics has granted its chief executive, Anders Lundstrom, options over 5,162,294 ordinary shares under its Retention and Performance Share Plan, equivalent to about 0.48% of the company’s AIM-listed share capital. The options, p...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Shield Therapeutics posts profitable Q1 as ACCRUFeR sales surge and CFO departs
Positive
May 1, 2026
Shield Therapeutics reported a sharp improvement in its first-quarter 2026 performance, with group net revenues rising to $18 million and EBIT turning positive at about $2.5 million, driven by a $7.9 million milestone payment from its Chinese part...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics Updates Total Voting Rights and Highlights Global Iron Therapy Franchise
Positive
Apr 30, 2026
Shield Therapeutics has confirmed that its issued share capital now comprises 1,068,418,471 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This updated total voting rights figure serves as the r...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Starts Japanese Phase II Trial of ACCRUFeR in Pulmonary Arterial Hypertension
Positive
Apr 27, 2026
Shield Therapeutics said partner MEDLEAP Pharma has enrolled the first patient in a Phase II clinical trial in Japan evaluating ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension. The exploratory study, endorsed ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
Positive
Apr 9, 2026
Shield Therapeutics reported its strongest year to date in 2025, driven by a 56% increase in U.S. ACCRUFeR net revenue to about $46 million, making the drug the number one branded prescription oral iron in the U.S. market. Group net revenues and o...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal
Positive
Apr 1, 2026
Shield Therapeutics has highlighted the growing clinical profile of its flagship ferric maltol product after an independent, peer-reviewed report on ACCRUFeR/FeRACCRU was published in the journal Pediatric Drugs. The paper reviews the recent U.S. ...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates share capital and underscores global iron deficiency franchise
Positive
Mar 31, 2026
Shield Therapeutics has confirmed that its issued share capital comprises 1,068,418,471 ordinary shares with equal voting rights and no shares held in treasury. This updated share count provides investors with the reference figure needed to assess...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents
Positive
Mar 31, 2026
Shield Therapeutics has secured a key regulatory win as the European Medicines Agency’s committee backed extending the indication for FeRACCRU to include adolescents, broadening its use for iron deficiency treatment in patients aged 12 and o...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance
Positive
Mar 3, 2026
Shield Therapeutics said China’s National Medical Products Administration has accepted a marketing authorisation application for its ferric maltol product ACCRUFeR, filed by local partner Beijing Aosaikang Pharmaceutical. The submission, bac...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues
Positive
Feb 27, 2026
Shield Therapeutics plc, a London-listed specialty pharmaceutical company, focuses on iron deficiency treatment through its innovative oral iron therapy ACCRUFeR/FeRACCRU, marketed globally via a network of regional partners. With FDA approval, br...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.